Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 0.84
NAVB's Cash to Debt is ranked higher than
56% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. NAVB: 0.84 )
NAVB' s 10-Year Cash to Debt Range
Min: 0.2   Max: No Debt
Current: 0.84

Equity to Asset -0.45
NAVB's Equity to Asset is ranked lower than
58% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. NAVB: -0.45 )
NAVB' s 10-Year Equity to Asset Range
Min: -3.6   Max: 0.94
Current: -0.45

-3.6
0.94
F-Score: 3
Z-Score: -15.61
M-Score: 21.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -3398.59
NAVB's Operating margin (%) is ranked lower than
57% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. NAVB: -3398.59 )
NAVB' s 10-Year Operating margin (%) Range
Min: -35429.11   Max: 13.25
Current: -3398.59

-35429.11
13.25
Net-margin (%) -3775.33
NAVB's Net-margin (%) is ranked lower than
57% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. NAVB: -3775.33 )
NAVB' s 10-Year Net-margin (%) Range
Min: -36907.59   Max: 938.63
Current: -3775.33

-36907.59
938.63
ROA (%) -105.91
NAVB's ROA (%) is ranked lower than
56% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. NAVB: -105.91 )
NAVB' s 10-Year ROA (%) Range
Min: -459.96   Max: 24.3
Current: -105.91

-459.96
24.3
ROC (Joel Greenblatt) (%) -1808.85
NAVB's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 13.69 vs. NAVB: -1808.85 )
NAVB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5206.05   Max: 148.79
Current: -1808.85

-5206.05
148.79
EBITDA Growth (%) -22.60
NAVB's EBITDA Growth (%) is ranked higher than
57% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. NAVB: -22.60 )
NAVB' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 141
Current: -22.6

0
141
EPS Growth (%) -23.10
NAVB's EPS Growth (%) is ranked higher than
59% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: -1.70 vs. NAVB: -23.10 )
NAVB' s 10-Year EPS Growth (%) Range
Min: 0   Max: 112.7
Current: -23.1

0
112.7
» NAVB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013
Q2 2013
Q4 2013
Q1 2014
» Details

Insider Trades

Latest Guru Trades with NAVB



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 93.30
NAVB's P/S is ranked lower than
51% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 3.28 vs. NAVB: 93.30 )
NAVB' s 10-Year P/S Range
Min: 0.82   Max: 203
Current: 93.3

0.82
203
EV-to-EBIT -5.36
NAVB's EV-to-EBIT is ranked higher than
55% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 44.62 vs. NAVB: -5.36 )
NAVB' s 10-Year EV-to-EBIT Range
Min: 4.2   Max: 50.9
Current: -5.36

4.2
50.9
Current Ratio 5.42
NAVB's Current Ratio is ranked higher than
87% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. NAVB: 5.42 )
NAVB' s 10-Year Current Ratio Range
Min: 0.65   Max: 17.92
Current: 5.42

0.65
17.92
Quick Ratio 5.03
NAVB's Quick Ratio is ranked higher than
88% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. NAVB: 5.03 )
NAVB' s 10-Year Quick Ratio Range
Min: 0.48   Max: 17.8
Current: 5.03

0.48
17.8

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 22.50
NAVB's Price/Median PS Value is ranked higher than
51% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 1.18 vs. NAVB: 22.50 )
NAVB' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 62.07
Current: 22.5

0.12
62.07
Earnings Yield (Greenblatt) 30.60
NAVB's Earnings Yield (Greenblatt) is ranked higher than
98% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. NAVB: 30.60 )
NAVB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2   Max: 31.7
Current: 30.6

2
31.7
Forward Rate of Return (Yacktman) 97.91
NAVB's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. NAVB: 97.91 )
NAVB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -231.1   Max: -88.5
Current: 97.91

-231.1
-88.5

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Navidea Biopharmaceuticals Inc is incorporated in Delaware. It is a biopharmaceutical company which is engaged in the development and commercialization of precision diagnostics and radiopharmaceutical agent. Its products include Gamma Detection Devices; Blood Flow Measurement Devices. Since October of 1999, its gamma detection systems have been marketed and distributed through Ethicon Endo-Surgery, Inc. 'EES', a Johnson & Johnson company. It has two radiopharmaceutical products, Lymphoseek and RIGScan, in advanced phases of clinical development. It faces competition from medical product and biotechnology companies, as well as from universities and other non-profit research organizations in the field of cancer diagnostics and treatment. As a developer, manufacturer and marketer of medical products, the Company is subject to regulation by, among other governmental entities, FDA and the corresponding state, local and foreign regulatory bodies in jurisdictions in which its products are sold.
» More Articles for NAVB

Headlines

Articles On GuruFocus.com
Navidea Biopharmaceuticals Reports 4 Insider Trades Mar 18 2013 
comment on NAVB Mar 15 2013 

More From Other Websites
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Jul 21 2014
Navidea Biopharmaceuticals Announces 2014 Annual Meeting Results Jul 17 2014
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 16 2014
Navidea Joins Essex Woodland’s Rheumco to Develop Radiopharmaceuticals for Detection and Treatment... Jul 16 2014
Navidea Joins Essex Woodland’s Rheumco to Develop Radiopharmaceuticals for Detection and Treatment... Jul 16 2014
Navidea to Webcast Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers July 8,... Jul 02 2014
Navidea to Webcast Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers July 8,... Jul 02 2014
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events,... Jun 16 2014
Navidea confirms FDA approval of expanded use for Lymphoseek Jun 13 2014
U.S. FDA Approves Navidea Biopharmaceuticals’ Lymphoseek® (technetium Tc 99m tilmanocept)... Jun 13 2014
Biotech Stock Mailbag: Vanda, Navidea, Provectus Jun 13 2014
Navidea (NAVB) Worth Watching: Stock Up 7.3% Jun 12 2014
Navidea announces results from post-hoc analysis from Lymphoseek injection trial Jun 11 2014
Navidea Biopharmaceuticals’ Lymphoseek® (technetium Tc 99m tilmanocept) Injection Demonstrates... Jun 11 2014
Navidea Biopharmaceuticals Announces Positive Lymphoseek® (technetium Tc 99m tilmanocept) Injection... Jun 10 2014
Navidea Announces Data Demonstrating Potential of Manocept™ Platform to Diagnose Rheumatoid... Jun 10 2014
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 02 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide